WASHINGTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo, CEO of Visus Therapeutics, discusses the results of the VIVID phase 2 study of presbyopia drop formulations in patients with emmetropic presbyopia.
VIDEO: Visus shares phase 2 results of presbyopia drop formulations
WASHINGTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo, CEO of Visus Therapeutics, discusses the results of the VIVID phase 2 study of presbyopia drop formulations in patients with emmetropic presbyopia.